OVID241220C7500
- 0.00
- 0.000.00%
Ovid Therapeutics Newsroom
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Ovid Therapeutics: Strategic Developments and Financial Stability Lead to Buy Rating
Ovid Therapeutics | 10-Q: Q3 2024 Earnings Report
Ovid Therapeutics | 8-K: Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics Reports Q3 EPS (20c), Consensus (20c)
Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000
Express News | Ovid Therapeutics Q3 Operating Expenses USD 13.399 Million
Express News | Ovid Therapeutics Q3 Net Income USD -14.006 Million
Press Release: Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics to Host Investor Event
12 Health Care Stocks Moving In Wednesday's After-Market Session
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate In Animal Eyes in Contrast With Vigabatrin
Ovid Therapeutics Presents Study Results on OV329